170 related articles for article (PubMed ID: 18757400)
1. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Cramer K; Nieborowska-Skorska M; Koptyra M; Slupianek A; Penserga ET; Eaves CJ; Aulitzky W; Skorski T
Cancer Res; 2008 Sep; 68(17):6884-8. PubMed ID: 18757400
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL stimulates WRN to promote survival and genomic instability.
Slupianek A; Poplawski T; Jozwiakowski SK; Cramer K; Pytel D; Stoczynska E; Nowicki MO; Blasiak J; Skorski T
Cancer Res; 2011 Feb; 71(3):842-51. PubMed ID: 21123451
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP.
Salles D; Mencalha AL; Ireno IC; Wiesmüller L; Abdelhay E
Carcinogenesis; 2011 Jan; 32(1):27-34. PubMed ID: 20974687
[TBL] [Abstract][Full Text] [Related]
4. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.
Rink L; Slupianek A; Stoklosa T; Nieborowska-Skorska M; Urbanska K; Seferynska I; Reiss K; Skorski T
Blood; 2007 Jul; 110(2):651-60. PubMed ID: 17431132
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.
Fernandes MS; Reddy MM; Gonneville JR; DeRoo SC; Podar K; Griffin JD; Weinstock DM; Sattler M
Blood; 2009 Aug; 114(9):1813-9. PubMed ID: 19571320
[TBL] [Abstract][Full Text] [Related]
6. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.
Nowicki MO; Falinski R; Koptyra M; Slupianek A; Stoklosa T; Gloc E; Nieborowska-Skorska M; Blasiak J; Skorski T
Blood; 2004 Dec; 104(12):3746-53. PubMed ID: 15304390
[TBL] [Abstract][Full Text] [Related]
7. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.
Slupianek A; Dasgupta Y; Ren SY; Gurdek E; Donlin M; Nieborowska-Skorska M; Fleury F; Skorski T
Blood; 2011 Jul; 118(4):1062-8. PubMed ID: 21653319
[TBL] [Abstract][Full Text] [Related]
8. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.
Slupianek A; Hoser G; Majsterek I; Bronisz A; Malecki M; Blasiak J; Fishel R; Skorski T
Mol Cell Biol; 2002 Jun; 22(12):4189-201. PubMed ID: 12024032
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Zhao R; Follows GA; Beer PA; Scott LM; Huntly BJ; Green AR; Alexander DR
N Engl J Med; 2008 Dec; 359(26):2778-89. PubMed ID: 19109573
[TBL] [Abstract][Full Text] [Related]
10. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
11. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts.
Skorski T
Leuk Lymphoma; 2008 Apr; 49(4):610-4. PubMed ID: 18398719
[TBL] [Abstract][Full Text] [Related]
12. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
13. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.
Slupianek A; Nowicki MO; Koptyra M; Skorski T
DNA Repair (Amst); 2006 Feb; 5(2):243-50. PubMed ID: 16297667
[TBL] [Abstract][Full Text] [Related]
14. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
Kulkarni S; Heath C; Parker S; Chase A; Iqbal S; Pocock CF; Kaeda J; Cwynarski K; Goldman JM; Cross NC
Cancer Res; 2000 Jul; 60(13):3592-8. PubMed ID: 10910073
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
Gross AW; Zhang X; Ren R
Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
[TBL] [Abstract][Full Text] [Related]
18. TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin.
Majsterek I; Slupianek A; Blasiak J
Anticancer Drugs; 2003 Sep; 14(8):625-31. PubMed ID: 14501384
[TBL] [Abstract][Full Text] [Related]
19. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
[TBL] [Abstract][Full Text] [Related]
20. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold.
Dierov J; Sanchez PV; Burke BA; Padilla-Nash H; Putt ME; Ried T; Carroll M
Leukemia; 2009 Feb; 23(2):279-86. PubMed ID: 19020542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
